Samuel qualified into the corporate department in 2017 and advises on a broad range of corporate transactional matters. Samuel has worked on a variety of transactions for technology-focussed and life sciences clients, from start-ups through to global pharmaceutical companies, drawing on his knowledge of those sectors from his time at Imperial College, London.
Samuel has experience in both investments and M&A deals, and in providing general corporate advice to clients, including advising publicly-listed entities on the UK law aspects of follow-on offerings on NASDAQ, and placings on AIM.
- BSc Biochemistry, Imperial College, London
- Qualified 2017